News

We invest in growth stage diagnostic companies and empower them with the full strength of our collective resources, capital, and expertise.

Sapphiros Awarded $11M from NIH RADx® Tech to Develop a Next-generation Molecular OTC Test

READ MORE

Sapphiros Taps Teresa Abraham for VP of Scientific and Technical Affairs

READ MORE

Biocrucible, a Sapphiros Company, Appoints Per Grufman as CEO

READ MORE

Sapphiros Appoints Mark Gladwell as CEO and President

READ MORE

Sapphiros Acquires Flexotronix Limited

READ MORE

Mike Musgnug Joins Sapphiros as Executive Vice President, Strategy and CEO, GrapheneDx

READ MORE